Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $191.31 Analyst target: $258.84 Upside: 35.30%
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
See the full interactive analysis & chart →Informational only — not investment advice.